Literature DB >> 3928496

An amphotericin B-resistant case of rhinocerebral mucor mycosis.

J Barnert, W Behr, H Reich.   

Abstract

A 51-year-old male patient with diabetes mellitus complicated by ketoacidotic imbalance developed a rhinocerebral mucor mycosis that advanced despite early amphotericin B therapy and extensive surgical intervention. The MIC of amphotericin B for the isolated mucor species was 64 mg/l, meaning that in vitro resistance also existed. Only long-term treatment with ketoconazole (600 mg/day, perorally) was successful in curing the disease.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3928496     DOI： 10.1007/bf01642873

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  8 in total

1.  Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum.

Authors:  G R GALE; A M WELCH
Journal:  Am J Med Sci       Date:  1961-05       Impact factor: 2.378

2.  Rhinocerebral phycomycosis in association with diabetic ketoacidosis. Report of two cases and a review of clinical and experimental experience with amphotericin B therapy.

Authors:  E Abramson; D Wilson; R A Arky
Journal:  Ann Intern Med       Date:  1967-04       Impact factor: 25.391

3.  [Generalized mucormycosis].

Authors:  R Siebenmann; T Wegmann
Journal:  Schweiz Med Wochenschr       Date:  1968-04-06

4.  Rhinocerebral mucormycosis: premortem diagnosis and therapy.

Authors:  B R Meyers; G Wormser; S Z Hirschman; A Blitzer
Journal:  Arch Intern Med       Date:  1979-05

Review 5.  Mucormycosis.

Authors: 
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

6.  Experimental cerebral mucormycosis in rabbits with alloxan diabetes.

Authors:  H BAUER; J F FLANAGAN; W H SHELDON
Journal:  Yale J Biol Med       Date:  1955-09

7.  The effects of metabolic alterations on experimental Rhizopus oryzae (mucormycosis) infection.

Authors:  H BAUER; J F FLANAGAN; W H SHELDON
Journal:  Yale J Biol Med       Date:  1956-09

8.  Leukopenia with granulocytopenia in experimental mucormycosis (Rhizopus oryzae infection).

Authors:  H BAUER; W H SHELDON
Journal:  J Exp Med       Date:  1957-10-01       Impact factor: 14.307
  8 in total
  7 in total

1.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

2.  Diabetes mellitus, fever, proptosis, and rapid loss of vision.

Authors:  R Goswami; N Tandon; S Thulkar; N Kochupillai
Journal:  Postgrad Med J       Date:  1996-10       Impact factor: 2.401

3.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 4.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

5.  Identification of fungal pathogens in a patient with acute myelogenic leukemia using a pathogen detection array technology.

Authors:  Sagarika Banerjee; Kristen N Peck; Michael D Feldman; Mindy G Schuster; James C Alwine; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

Review 6.  Opportunistic zygomycotic infections. A literature review.

Authors:  A Espinel-Ingroff; L A Oakley; T M Kerkering
Journal:  Mycopathologia       Date:  1987-01       Impact factor: 2.574

7.  In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.

Authors:  M Otcenásek; V Buchta
Journal:  Mycopathologia       Date:  1994-12       Impact factor: 2.574
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.